Kari Simonsen
Pediatric Infectious Diseases · Omaha, NENPI 1154525806
Payments from drug & device makers
$881,786in general payments, 2019–2025
Across 121 payments — averaging $7287.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$713K
- AstraZeneca$95K
- Melinta Therapeutics, LLC$40K
- Astrazeneca UK Limited$34K
- Merck$20
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 61 | $713,318 |
| AstraZeneca | 10 | $94,742 |
| Melinta Therapeutics, LLC | 45 | $40,057 |
| Astrazeneca UK Limited | 4 | $33,648 |
| Merck | 1 | $20 |
How this compares
Too few pediatric infectious diseases providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Other pediatric infectious diseases in Omaha
- Herbert DaviesOmaha$46K
- Shirley DelairOmaha$39K
- Kari NeemannOmaha$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.